Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
Ohtani S, Nakayama T, Yoshinami T, Watanabe KI, Hara F, Sagara Y, Kawaguchi H, Higaki K, Matsunami N, Hasegawa Y, Takahashi M, Mizutani M, Morimoto T, Sato M, Itoh M, Morita S, Masuda N. Ohtani S, et al. Breast Cancer. 2018 Jul;25(4):438-446. doi: 10.1007/s12282-018-0843-y. Epub 2018 Feb 12. Breast Cancer. 2018. PMID: 29435730 Free PMC article. Clinical Trial.
Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients.
Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, Yamamoto Y, Nishimura R, Sato N, Ohsumi S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Lu DR, Toi M. Mukai H, et al. Among authors: ohtani s. Int J Clin Oncol. 2019 Mar;24(3):274-287. doi: 10.1007/s10147-018-1353-9. Epub 2018 Dec 4. Int J Clin Oncol. 2019. PMID: 30515674 Free PMC article. Clinical Trial.
Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Kawaguchi H, et al. Among authors: ohtani s. Breast Cancer. 2020 May;27(3):389-398. doi: 10.1007/s12282-019-01029-3. Epub 2019 Dec 6. Breast Cancer. 2020. PMID: 31811519 Free PMC article.
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K, Yasojima H, Kasai H, Takasuka T, Sakurai T, Kataoka TR, Morita S, Ohno S, Toi M. Masuda N, et al. Among authors: ohtani s. Breast Cancer Res Treat. 2020 Feb;180(1):135-146. doi: 10.1007/s10549-020-05524-6. Epub 2020 Jan 17. Breast Cancer Res Treat. 2020. PMID: 31953696 Free PMC article.
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
Yamashiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Kuroi K, Takano T, Yasuno S, Morita S, Ohno S, Toi M; JBCRG-C01 Collaborative Group. Yamashiro H, et al. Among authors: ohtani s. Breast Cancer. 2020 Jul;27(4):631-641. doi: 10.1007/s12282-020-01057-4. Epub 2020 Feb 14. Breast Cancer. 2020. PMID: 32060785 Free PMC article.
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Ishiguro H, Masuda N, Sato N, Higaki K, Morimoto T, Yanagita Y, Mizutani M, Ohtani S, Kaneko K, Fujisawa T, Takahashi M, Kadoya T, Matsunami N, Yamamoto Y, Ohno S, Takano T, Morita S, Tanaka-Mizuno S, Toi M. Ishiguro H, et al. Among authors: ohtani s. Breast Cancer Res Treat. 2020 Apr;180(3):715-724. doi: 10.1007/s10549-020-05590-w. Epub 2020 Mar 13. Breast Cancer Res Treat. 2020. PMID: 32170634 Free PMC article. Clinical Trial.
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
Yamamoto Y, Yamashiro H, Toh U, Kondo N, Nakamura R, Kashiwaba M, Takahashi M, Tsugawa K, Ishikawa T, Nakayama T, Ohtani S, Takano T, Fujisawa T, Toyama T, Kawaguchi H, Mashino K, Tanino Y, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: ohtani s. Breast Cancer. 2021 Jan;28(1):145-160. doi: 10.1007/s12282-020-01138-4. Epub 2020 Jul 26. Breast Cancer. 2021. PMID: 32715420 Free PMC article.
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawaguchi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S. Aogi K, et al. Among authors: ohtani s. Int J Clin Oncol. 2021 Jul;26(7):1229-1236. doi: 10.1007/s10147-021-01920-0. Epub 2021 Apr 23. Int J Clin Oncol. 2021. PMID: 33891194 Free PMC article. Clinical Trial.
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawagichi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, Ohno S. Aogi K, et al. Among authors: ohtani s. Int J Clin Oncol. 2021 Jul;26(7):1237. doi: 10.1007/s10147-021-01940-w. Int J Clin Oncol. 2021. PMID: 34043103 Free PMC article. No abstract available.
471 results